LANXESS IS NO GERMAN ARKEMA QUITE YET (REDUCE; +8% UPSIDE)

01/10/24 -" Lanxess’ (Reduce; Germany) equity story is a difficult one. At first sight, the company seems to have the portfolio rotation gene, but there is hardly any positive effect to be identified. Lanxess ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

01/10/24

Download

You may also be interested by these reports :

11/10/24

K+S

Estimates fine-tuned ahead of 3Q24E results

10/10/24

KWS SAAT SE & Co. KGaA

Divestment closed in 1Q24/25, now collecting cash and investing into growth in core and vegetables

10/10/24

Givaudan

Another beat on expectations but expecting more normalized 4Q24E

08/10/24

Siltronic AG

Despite an increase in the EPS, DCF and SOTP-derived valuations, the overall target price has declined due to a dividend reduction to €1.00 per ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue